Welcome to CDC stacks | HPV Vaccination and Complex Regional Pain Syndrome: Lack of Evidence - 37742 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
HPV Vaccination and Complex Regional Pain Syndrome: Lack of Evidence
Filetype[PDF-147.88 KB]


Details:
No Related Documents.
You May Also Like:
  1. Adverse events following 9-valent human papillomavirus vaccine (9vHPV) reported to the Vaccine Adverse Event Reporting System (VAERS)
    Personal Author:
    Arana, Jorge
    Corporate Author:
    National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Immunization Safety Office.
    Conference Author:
    United States. Advisory Committee on Immunization Practices. Meeting (2018 February 21-22 : Atlanta, GA)
    Published:
    4/19/18
    Series:
    ACIP meeting Human Papillomavirus (HPV) Vaccines Update
    Description:
    Presentations February 2018 Day 1 : Publication date from document properties. : HPV-02-Arana-508.pdf
    File Type:
    Filetype[PDF - 522.88 KB]
  2. Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
    Personal Author:
    Gee, Julianne; Weinbaum, Cindy; Sukumaran, Lakshmi; Markowitz, Lauri E.;
    Published:
    Mar 30 2016
    Source:
    Hum Vaccin Immunother. 2016; 12(6):1406-1417.
    Description:
    Quadrivalent human papillomavirus (4vHPV) vaccine was licensed for use in the United States in 2006 and through 2015 was the predominate HPV vaccine used. With the exception of syncope, a known preventable adverse event after any injected vaccination...
    File Type:
    Filetype[PDF - 446.81 KB]
  3. Human papillomavirus (HPV)vaccine safety update
    Personal Author:
    Sukumaran, Lakshmi
    Corporate Author:
    National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion. Immunization Safety Office.
    Conference Author:
    United States. Advisory Committee on Immunization Practices. Meeting (2015 October 21 : Atlanta, GA)
    Published:
    October 21, 2015
    Series:
    ACIP meeting Human Papillomavirus (HPV) Vaccines Update
    File Type:
    Filetype[PDF - 209.85 KB]
  4. Record of the meeting of the Advisory Committee on Immunization Practices : October 26-27, 2005
    Corporate Author:
    United States. Advisory Committee on Immunization Practices.. National Immunization Program (Centers for Disease Control and Prevention).
    Conference Author:
    United States. Advisory Committee on Immunization Practices. Meeting (2005 October 26-27 : Atlanta, GA)
    Published:
    2005
    Series:
    ACIP meeting Minutes
    Description:
    Publication date from document properties. : 2005_10 minutes.pdf
    File Type:
    Filetype[PDF - 466.29 KB]
  5. 2463. Post-licensure Surveillance of 9-Valent Human Papillomavirus Vaccine (9vHPV) in the Vaccine Adverse Event Reporting System (VAERS), United States, 2014–2017
    Personal Author:
    Arana, Jorge; Su, John; Lewis, Paige; Cano, Maria; Markowitz, Lauri E; Shimabukuro, Tom;
    Conference Author:
    IDWeek (2018 October 3-7 : San Franciso, CA)
    Published:
    Nov 26 2018
    Source:
    Open Forum Infect Dis. 2018; 5(Suppl 1):S738.
    Description:
    Background : 9-valent human papillomavirus vaccine (9vHPV) was licensed in December 2014 and recommended by the Advisory Committee on Immunization Practices (ACIP) in February 2015. 9vHPV is FDA-approved for females and males aged 9–26 years; ACIP ...
    File Type:
    Filetype[PDF - 59.88 KB]